A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction

NCT00073502 Phase 2 COMPLETED

Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.

Details

Lead sponsor	OSI Pharmaceuticals
Phase	Phase 2
Status	COMPLETED
Enrolment	43
Start date	2003-10
Completion	2003-10

Conditions

• Gastroesophageal Adenocarcinoma
• Gastric Adenocarcinoma

Interventions

• OSI-7904L

Countries

United States, Belgium, United Kingdom